PharmAbcine Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jin-San Yoo

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	16.3yrs
Proprietà del CEO	0.9%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

PharmAbcine (KOSDAQ:208340) Has Debt But No Earnings; Should You Worry?

Mar 29

Health Check: How Prudently Does PharmAbcine (KOSDAQ:208340) Use Debt?

Dec 14

AMMINISTRATORE DELEGATO

Jin-San Yoo

16.3yrs

Mandato

Dr. Jin-San Yoo founded PharmAbcine Inc. in 2008 and serves as its Chief Executive Officer and President and serves as its President of R&D, CSO & CBO from March 2024 and served as its Director until March...

PharmAbcine Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

No independent directors

No independent directors

PharmAbcine, Inc., Annual General Meeting, Mar 25, 2021

Recent updates

PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration

PharmAbcine Announces Safety Approval for the First Dose Cohort in Phase 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors

PharmAbcine Inc. Announces its Phase 1 Clinical Trial of PMC-403 for Neovascular Age-Related Macular Degeneration Advances to Both Single-Dose of 4mg and Multiple-Dose of 3mg

PharmAbcine Inc. Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA®? (Pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors

New minor risk - Shareholder dilution

New major risk - Financial position

Pharmabcine, Inc. Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-Related Macular Degeneration Following Dose Level 1 Safety Data

New major risk - Share price stability

New minor risk - Share price stability

PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of its Novel TIE2 Agonistic Antibody in nAMD

Full year 2022 earnings released: ₩1,190 loss per share (vs ₩2,126 loss in FY 2021)

No independent directors

Pharmabcine Inc. Announces the Positive Results from the GLP Toxicology Study of PMC-403, the Company's Novel TIE2-Activating Antibody

No independent directors

PharmAbcine Inc. announced that it expects to receive KRW 10 billion in funding from Kiwoom Asset Management Co., Ltd., Hanyang Securities Co. Ltd., NH Investment & Securities Co., Ltd., Investment Arm and other investors

PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022

PharmAbcine to Present Updated Data of Its Anti-VISTA Antibody Candidate at AACR 2022

PharmAbcine Inc. Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial

PharmAbcine Inc. Announces First Patient Enrolled and Dosed in the Phase Ii Clinical Trial for the Treatment of mTNBC

PharmAbcine, Inc. Announces Joint Patent Application with MSD for the Treatment of Cancer

PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC

PharmAbcine Announces Submission of PCT for an Anti-ANG2 Antibody for the Treatment of Ocular Diseases

PharmAbcine, Inc. has completed a Follow-on Equity Offering in the amount of KRW 51.093 billion.

PharmAbcine Announces Encouraging Non-clinical Data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

PharmAbcine (KOSDAQ:208340) Has Debt But No Earnings; Should You Worry?

New 90-day low: ₩17,900

PharmAbcine, Inc., Annual General Meeting, Mar 25, 2021

New 90-day high: ₩23,500

PharmAbcine Inc. Announces Research Collaboration with Legochem Biosciences

New 90-day high: ₩22,750

Health Check: How Prudently Does PharmAbcine (KOSDAQ:208340) Use Debt?

PharmAbcine Inc. Presents the Latest Data of the Ongoing Phase Ib mTNBC Trial at SABCS 2020

New 90-day low: ₩18,400

PharmAbcine, Inc. Announces to Present the Final Data of Phase IIa rGBM trial at SNO 2020

PharmAbcine Expands Partnership with Samsung Biologics for PMC-403

Pharmabcine Unveils Olinvacimab's Positive Results from Phase Ib Combination Studies At KSMO 2020

AMMINISTRATORE DELEGATO

Mandato